Arrowstreet Capital Limited Partnership Buys Shares of 91,022 Omada Health, Inc. $OMDA

Key Points

• Arrowstreet Capital initiated a position in Omada Health, purchasing 91,022 shares valued at approximately $1.14 million, or about 0.15% of the company. Other institutional investors, including Walleye Capital and Bank of New York Mellon, also increased their holdings.
• Omada Health reported stronger-than-expected quarterly results, with revenue up 43% year over year and members increasing 45%. The company forecast 2026 revenue of $334 million to $340 million, above the $327.2 million analyst consensus.
• Analyst sentiment remains broadly positive, with an average “Moderate Buy” rating and a $24.75 consensus price target, although insiders sold more than 206,000 shares worth approximately $4.19 million last quarter. The company also announced that co-founder Sean Duffy will transition to executive chair while President Wei-Li Shao becomes CEO in 2027.

Arrowstreet Capital Limited Partnership purchased a new stake in Omada Health, Inc. (NASDAQ:OMDA - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 91,022 shares of the company's stock, valued at approximately $1,144,000. Arrowstreet Capital Limited Partnership owned about 0.15% of Omada Health as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the business. Sei Investments Co. acquired a new stake in shares of Omada Health in the 1st quarter valued at approximately $196,000. Walleye Capital LLC boosted its holdings in shares of Omada Health by 677.2% during the 1st quarter. Walleye Capital LLC now owns 352,443 shares of the company's stock valued at $4,430,000 after acquiring an additional 307,097 shares in the last quarter. a16z Perennial Management L.P. boosted its holdings in shares of Omada Health by 22.5% during the 1st quarter. a16z Perennial Management L.P. now owns 192,466 shares of the company's stock valued at $2,365,000 after acquiring an additional 35,334 shares in the last quarter. Bank of New York Mellon Corp grew its position in Omada Health by 284.5% during the 1st quarter. Bank of New York Mellon Corp now owns 75,681 shares of the company's stock worth $951,000 after acquiring an additional 55,996 shares during the last quarter. Finally, Fifth Third Bancorp bought a new position in Omada Health in the first quarter valued at about $127,000.

Analysts Set New Price Targets

Several research firms have recently weighed in on OMDA. BTIG Research assumed coverage on Omada Health in a report on Friday, July 17th. They set a "buy" rating and a $30.00 price target on the stock. Wall Street Zen lowered shares of Omada Health from a "buy" rating to a "hold" rating in a report on Saturday, July 18th. Needham & Company LLC reiterated a "buy" rating and set a $28.00 target price on shares of Omada Health in a research report on Friday, May 8th. Morgan Stanley reissued an "overweight" rating and set a $30.00 target price on shares of Omada Health in a report on Monday, June 22nd. Finally, Citigroup reaffirmed an "outperform" rating on shares of Omada Health in a research note on Monday, July 20th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Omada Health presently has an average rating of "Moderate Buy" and a consensus price target of $24.75.

Key Omada Health News

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Quarterly results beat expectations. Omada reported adjusted earnings of $0.15 per share, up from a $0.09 loss a year earlier and above the $0.05 consensus estimate. Another earnings summary reported EPS of $0.08 versus an expected loss of $0.02, reinforcing that results exceeded forecasts. Omada Health Q2 earnings and revenues top estimates
• Positive Sentiment: Growth remained strong. Second-quarter revenue rose 43% year over year, while total members increased 45%. Gross margin also reached a new quarterly record, supporting the company’s growth and profitability narrative. Omada Health reports second-quarter 2026 results
• Positive Sentiment: Full-year revenue guidance exceeded Wall Street expectations. Omada forecast fiscal 2026 revenue of $334 million to $340 million, above the $327.2 million analyst consensus. This suggests management expects sustained demand for its digital chronic-care programs.
• Neutral Sentiment: Leadership transition adds an execution consideration. Co-founder and CEO Sean Duffy will become executive chair on January 1, 2027, while President Wei-Li Shao becomes CEO. The planned, internal succession may provide continuity, although investors will monitor whether the change affects growth execution.
• Negative Sentiment: CEO insider selling provided a modest counterpoint. Duffy sold 12,944 shares for approximately $264,000, reducing his direct ownership by 3.05%. While the sale may have been for personal or financial-planning reasons, insider selling can weigh on sentiment.

Omada Health Stock Performance

NASDAQ:OMDA opened at $19.54 on Friday. Omada Health, Inc. has a fifty-two week low of $10.28 and a fifty-two week high of $26.92. The company has a 50 day simple moving average of $20.24 and a two-hundred day simple moving average of $16.15. The company has a market capitalization of $1.16 billion, a PE ratio of -72.37 and a beta of 1.73.

Omada Health (NASDAQ:OMDA - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.02) by $0.10. Omada Health had a negative net margin of 2.22% and a negative return on equity of 1.82%. Research analysts predict that Omada Health, Inc. will post -0.01 EPS for the current year.

Insider Buying and Selling

In other Omada Health news, CAO Craig Gracey sold 6,894 shares of the stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $17.42, for a total transaction of $120,093.48. Following the completion of the sale, the chief accounting officer directly owned 9,191 shares in the company, valued at approximately $160,107.22. This trade represents a 42.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Steven L. Cook sold 33,000 shares of Omada Health stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $19.89, for a total value of $656,370.00. Following the completion of the transaction, the chief financial officer directly owned 133,359 shares of the company's stock, valued at approximately $2,652,510.51. This trade represents a 19.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 206,406 shares of company stock valued at $4,191,483 over the last quarter. Insiders own 6.38% of the company's stock.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company's platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source